Bank of New York Mellon Corp Grows Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Bank of New York Mellon Corp increased its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 18.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 488,721 shares of the biotechnology company’s stock after buying an additional 77,510 shares during the period. Bank of New York Mellon Corp’s holdings in Aurinia Pharmaceuticals were worth $2,791,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. HighMark Wealth Management LLC increased its stake in Aurinia Pharmaceuticals by 3.0% during the 1st quarter. HighMark Wealth Management LLC now owns 75,196 shares of the biotechnology company’s stock worth $377,000 after buying an additional 2,197 shares during the period. ProShare Advisors LLC increased its stake in Aurinia Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock worth $173,000 after buying an additional 2,873 shares during the period. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $30,000. Tidemark LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $39,000. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Aurinia Pharmaceuticals by 7.1% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 75,787 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 5,043 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Up 6.8 %

NASDAQ AUPH opened at $7.03 on Monday. Aurinia Pharmaceuticals Inc. has a one year low of $4.71 and a one year high of $10.05. The company has a 50-day simple moving average of $6.06 and a 200-day simple moving average of $5.55. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.82 and a current ratio of 5.33. The firm has a market capitalization of $1.01 billion, a PE ratio of -16.35 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The business had revenue of $57.10 million during the quarter, compared to analyst estimates of $54.25 million. During the same period in the previous year, the business posted ($0.08) EPS. The company’s quarterly revenue was up 37.6% on a year-over-year basis. On average, equities analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

AUPH has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Insider Activity

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the transaction, the insider now directly owns 456,338 shares of the company’s stock, valued at approximately $2,423,154.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.